ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Grants ODD for Esophageal, Gastroesophageal Junction, Pancreatic Cancer Treatment
October 21, 2020Apexigen announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer. -
Leap Therapeutics announces orphan drug designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer
June 17, 2020Leap Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer.
Pharma Sources Insight January 2025
